相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
Gergely Varga et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Xavier Leleu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2018)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Roman Hajek et al.
BLOOD (2018)
Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Nizar Bahlis et al.
BLOOD (2018)
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
Maria-Victoria Mateos et al.
HAEMATOLOGICA (2017)
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
Chrissy H. Y. van Beurden-Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
Maria-Victoria Mateos et al.
HAEMATOLOGICA (2017)
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Herve Avet-Loiseau et al.
BLOOD (2017)
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K. Kumar et al.
BLOOD (2016)
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity
Luciano J. Costa et al.
LEUKEMIA & LYMPHOMA (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Paul G. Richardson et al.
BLOOD (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients
Jiri Minarik et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib
Ludek Pour et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
分享论文
